Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MNMD Mind Medicine (MindMed) Inc.

Trading 01-13 15:08:30 EST

14.86

+0.98

+7.06%

High15.20	Low13.83	Vol2.44M
Open13.92	D1 Closing13.88	Amplitude9.86%
Mkt Cap1.46B	Tradable Cap1.36B	Total Shares98.51M
T/O35.78M	T/O Rate2.68%	Tradable Shares91.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MNMD","market":"US","secType":"STK","nameCN":"Mind Medicine (MindMed) Inc.","latestPrice":14.86,"timestamp":1768334910507,"preClose":13.88,"halted":0,"volume":2443549,"delay":0,"floatShares":91334800,"shares":98509279,"eps":-1.975783,"marketStatus":"Trading","change":0.98,"latestTime":"01-13 15:08:30 EST","open":13.92,"high":15.2,"low":13.8311,"amount":35783270.467275,"amplitude":0.098624,"askPrice":14.88,"askSize":440,"bidPrice":14.84,"bidSize":101,"shortable":3,"etf":0,"ttmEps":-1.975783,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1768338000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":13.88,"preHourTrading":{"tag":"盘前","latestPrice":13.82,"preClose":13.88,"latestTime":"09:20 EST","volume":2236,"amount":31176.641912,"timestamp":1768314042075},"postHourTrading":{"tag":"盘后","latestPrice":13.88,"preClose":13.88,"latestTime":"19:59 EST","volume":64956,"amount":900336.747,"timestamp":1768265991136},"volumeRatio":1.170286,"impliedVol":0.7416,"impliedVolPercentile":0.2112},"requestUrl":"/m/hq/s/MNMD","defaultTab":"news","newsList":[{"id":"2602512636","title":"Mind Medicine rebrands to Definium Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512636?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:11","pubTimestamp":1768219919,"startTime":"0","endTime":"0","summary":"Definium Therapeutics, formerly Mind Medicine (MNMD), unveiled its new brand. In conjunction with the rebrand, the company’s Nasdaq ticker symbol w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mind-medicine-rebrands-to-definium-therapeutics-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mind-medicine-rebrands-to-definium-therapeutics-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4547","BK4139","NQmain","MNMD","BK4539","LENZ"],"gpt_icon":0},{"id":"2602147475","title":"Mind Medicine (MindMed) Inc: Company Shares Will Trade Under New Nasdaq Ticker Symbol \"Dftx\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2602147475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602147475?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:08","pubTimestamp":1768219687,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0PN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BK4007","MNMD"],"gpt_icon":0},{"id":"2602351196","title":"MindMed Highlights Phase 3 Progress and Billion-Dollar Potential in Anxiety and Depression Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2602351196","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602351196?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:41","pubTimestamp":1768218118,"startTime":"0","endTime":"0","summary":"Mind Medicine  Inc. has highlighted progress across its therapeutic pipeline, with three Phase 3 clinical trial readouts anticipated in 2026 for the treatment of generalized anxiety disorder  and major depressive disorder . The company emphasizes the significant unmet need in psychiatry due to limited and recycled treatment options for anxiety and depressive disorders, which affect over 50 million people and are growing at an annual rate of over 5%. Recent Phase 2b studies demonstrated a statistically significant dose response, supporting 100 g as the optimal dose for further development. The findings suggest the results are robust and unlikely to be explained by functional unblinding. MindMed is advancing multiple product candidates, including lysergide tartrate for MDD and DT4022  for autism spectrum disorder, through various stages of clinical development. You can access the full presentation through the link below.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL7hzFnH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MNMD","BK4547"],"gpt_icon":0},{"id":"2593132754","title":"Mind Medicine MindMed Initiated at Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2593132754","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593132754?lang=en_us&edition=fundamental","pubTime":"2025-12-23 22:07","pubTimestamp":1766498820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 23, 2025 09:07 ET (14:07 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","MNMD","BK4007"],"gpt_icon":0},{"id":"2591621297","title":"MindMed Grants Stock Options to New Employees as Hiring Incentive","url":"https://stock-news.laohu8.com/highlight/detail?id=2591621297","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591621297?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:01","pubTimestamp":1765832472,"startTime":"0","endTime":"0","summary":"Mind Medicine  Inc. has announced the issuance of inducement grants to two newly hired non-executive employees. The grants consist of options to purchase a total of 31,500 common shares, with the grant date set for December 15, 2025. The exercise price for these options will match the closing price of MindMed's common shares on the grant date. Vesting will occur over four years, with 25% of the options vesting on the first anniversary of the grant date and the remaining 75% vesting in equal monthly increments over the next three years, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine  Inc. published the original content used to generate this news brief via Business Wire  on December 15, 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLcvWP3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD","BK4007","BK4547"],"gpt_icon":0},{"id":"2588708291","title":"MindMed Grants Stock Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2588708291","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588708291?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:01","pubTimestamp":1764622874,"startTime":"0","endTime":"0","summary":"Mind Medicine  Inc. has issued inducement grants to four newly hired non-executive employees. The grants consist of options to purchase a total of 182,100 common shares, with grant dates tied to each employee's start date in November and December 2025. The options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting in equal monthly increments over the following three years. The exercise price for the options will be equal to the closing price of the company's common shares on the respective grant dates.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine  Inc. published the original content used to generate this news brief via Business Wire  on December 01, 2025, and is solely respons","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDLRXNX7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4007","MNMD"],"gpt_icon":0},{"id":"2584296399","title":"MindMed Q3 Net Income USD -67.265 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584296399","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584296399?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:58","pubTimestamp":1763571484,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - MindMed Q3 operating expenses USD 45.669 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202521:01:46.967 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2KtpSc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4547","MNMD"],"gpt_icon":0},{"id":"1191839451","title":"Stock Track | Mind Medicine (MindMed) Soars 5.28% Following H.C. Wainwright's Buy Rating Reiteration","url":"https://stock-news.laohu8.com/highlight/detail?id=1191839451","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191839451?lang=en_us&edition=fundamental","pubTime":"2025-11-12 03:00","pubTimestamp":1762887626,"startTime":"0","endTime":"0","summary":"Shares of Mind Medicine (MindMed) Inc. (MNMD) surged 5.28% in intraday trading on Tuesday, following a bullish report from H.C. Wainwright. The biotech company, known for its work in...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MNMD"],"gpt_icon":0},{"id":"1182264596","title":"Stock Track | Mind Medicine (MindMed) Soars 5.28% Following H.C. Wainwright's Buy Rating Reiteration","url":"https://stock-news.laohu8.com/highlight/detail?id=1182264596","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182264596?lang=en_us&edition=fundamental","pubTime":"2025-11-12 03:00","pubTimestamp":1762887626,"startTime":"0","endTime":"0","summary":"Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) saw its stock soar 5.28% in intraday trading on Tuesday, following a positive analyst report from H.C. Wainwright. The surge in stock price comes as...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MNMD"],"gpt_icon":0},{"id":"2582365142","title":"H.C. Wainwright Sticks to Its Buy Rating for Mind Medicine (MNMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582365142","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582365142?lang=en_us&edition=fundamental","pubTime":"2025-11-11 19:55","pubTimestamp":1762862150,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Mind Medicine, with a price target of $55.00. Trucchio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-mind-medicine-mnmd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-mind-medicine-mnmd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNMD"],"gpt_icon":0},{"id":"1119978065","title":"Stock Track | Mind Medicine (MindMed) Soars 5.38% After Evercore ISI Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1119978065","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119978065?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:45","pubTimestamp":1762785906,"startTime":"0","endTime":"0","summary":"Shares of Mind Medicine (MindMed) Inc. (MNMD) are soaring in pre-market trading on Monday, with the stock price surging 5.38% to reach new heights. This significant uptick comes as investors react...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MNMD"],"gpt_icon":0},{"id":"1122210431","title":"Stock Track | Mind Medicine (MindMed) Soars 5.38% as Evercore ISI Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1122210431","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122210431?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:45","pubTimestamp":1762785904,"startTime":"0","endTime":"0","summary":"Shares of Mind Medicine (MindMed) Inc. (MNMD) are soaring 5.38% in pre-market trading on Monday, following a positive analyst report from Evercore ISI. The surge comes as investors react to the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MNMD"],"gpt_icon":0},{"id":"2582887270","title":"Mind Medicine (MNMD) Receives a Buy from Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2582887270","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582887270?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:18","pubTimestamp":1762784319,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst maintained a Buy rating on Mind Medicine today and set a price target of $23.00. In a report released on November 7, Canaccord...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mind-medicine-mnmd-receives-a-buy-from-evercore-isi-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mind-medicine-mnmd-receives-a-buy-from-evercore-isi-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","MNMD","BK4007"],"gpt_icon":0},{"id":"2581834210","title":"Mind Medicine MindMed Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2581834210","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581834210?lang=en_us&edition=fundamental","pubTime":"2025-11-08 06:01","pubTimestamp":1762552860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 17:01 ET (22:01 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4547","MNMD"],"gpt_icon":0},{"id":"2581880358","title":"RBC Adjusts Price Target on Mind Medicine to $20 From $21, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581880358","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581880358?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:45","pubTimestamp":1762533932,"startTime":"0","endTime":"0","summary":"Mind Medicine (MNMD) has an average rating of buy and mean price target of $25.64, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4547","BK4007","MNMD"],"gpt_icon":0},{"id":"2581026170","title":"Mind Medicine price target raised to $25 from $16 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2581026170","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581026170?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:55","pubTimestamp":1762516512,"startTime":"0","endTime":"0","summary":"Canaccord raised the firm’s price target on Mind Medicine (MNMD) to $25 from $16 and keeps a Buy rating on the shares. The firm added its MDD drug ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mind-medicine-price-target-raised-to-25-from-16-at-canaccord-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mind-medicine-price-target-raised-to-25-from-16-at-canaccord-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","ABVC","MNMD","BK4139","BK4007"],"gpt_icon":0},{"id":"2581046625","title":"Mind Medicine (MindMed) Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2581046625","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581046625?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:01","pubTimestamp":1762466471,"startTime":"0","endTime":"0","summary":"Mind Medicine (MindMed) Inc reports results for the quarter ended September 30 - Earnings SummaryMind Medicine (MindMed) Inc MNMD.OQ reported a quarterly adjusted loss of 78 cents per share for the qu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL8N3WI3VA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4007","MNMD"],"gpt_icon":0},{"id":"2581043641","title":"MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2581043641","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581043641?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:29","pubTimestamp":1762464542,"startTime":"0","endTime":"0","summary":"Mind Medicine  Inc. has released a corporate presentation highlighting ongoing developments in its late-stage pipeline focused on brain health, particularly targeting generalized anxiety disorder  and major depressive disorder . The company reports that its lead clinical program, MM120 ODT, is currently the subject of Phase 3 studies in both indications, with three Phase 3 topline readouts anticipated in 2026. MindMed states that it has a strong financial position, with cash and investments totaling $209.1 million as of September 30, 2025, and an additional $242.8 million raised in October 2025, supporting operations into 2028. The presentation also notes issued patents for MM120 ODT covering formulation, manufacturing, and treatment methods, with patent protection through 2041. Upcoming milestones include Phase 3 readouts for GAD and MDD programs, as well as the initiation of further studies. You can access the full presentation through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL4gWQ53:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4007","MNMD"],"gpt_icon":0},{"id":"2581201074","title":"MindMed Q3 net loss widens to $67.3 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2581201074","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581201074?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:15","pubTimestamp":1762463701,"startTime":"0","endTime":"0","summary":"MindMed Q3 net loss widens to $67.3 mlnOverviewMindMed Q3 net loss widens to $67.3 mln, driven by increased R&D and G&A expensesCompany completed public offering, raising $242.8 mln in net proceedsRes","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD","BK4007","BK4547"],"gpt_icon":0},{"id":"2581127660","title":"MindMed reports Q3 2025 results and updates cash position","url":"https://stock-news.laohu8.com/highlight/detail?id=2581127660","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581127660?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:02","pubTimestamp":1762462947,"startTime":"0","endTime":"0","summary":"Mind Medicine  Inc. reported cash, cash equivalents, and investments totaling $209.1 million as of September 30, 2025, down from $273.7 million at the end of 2024. The company completed a public offering on October 31, 2025, with net proceeds of $242.8 million. MindMed stated that these funds are expected to support operations into 2028. Key business developments include ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet  in generalized anxiety disorder  with topline data expected in the first and second halves of 2026, and an accelerated topline data readout for the first Phase 3 study of MM120 ODT in major depressive disorder  now expected in mid-2026. A Phase 2a study of MM402 in autism spectrum disorder  is planned to begin in the fourth quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL6N1MgL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MNMD","BK4547"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mindmed.co","stockEarnings":[{"period":"1week","weight":0.0221},{"period":"1month","weight":0.106},{"period":"3month","weight":0.0998},{"period":"6month","weight":0.6177},{"period":"1year","weight":1.0029},{"period":"ytd","weight":0.0366}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.085682},{"month":2,"riseRate":0.75,"avgChangeRate":0.162614},{"month":3,"riseRate":0.25,"avgChangeRate":0.069329},{"month":4,"riseRate":0.75,"avgChangeRate":0.007711},{"month":5,"riseRate":0.4,"avgChangeRate":-0.002468},{"month":6,"riseRate":0.4,"avgChangeRate":-0.111207},{"month":7,"riseRate":0.8,"avgChangeRate":0.20763},{"month":8,"riseRate":0.2,"avgChangeRate":-0.091548},{"month":9,"riseRate":0.2,"avgChangeRate":-0.174855},{"month":10,"riseRate":0.6,"avgChangeRate":0.009639},{"month":11,"riseRate":0.4,"avgChangeRate":0.026551},{"month":12,"riseRate":0.4,"avgChangeRate":-0.08416}],"exchange":"NASDAQ","name":"Mind Medicine (MindMed) Inc.","nameEN":"Mind Medicine (MindMed) Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mind Medicine (MindMed) Inc.(MNMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mind Medicine (MindMed) Inc.,MNMD,Mind Medicine (MindMed) Inc.股票,Mind Medicine (MindMed) Inc.股票老虎,Mind Medicine (MindMed) Inc.股票老虎国际,Mind Medicine (MindMed) Inc.行情,Mind Medicine (MindMed) Inc.股票行情,Mind Medicine (MindMed) Inc.股价,Mind Medicine (MindMed) Inc.股市,Mind Medicine (MindMed) Inc.股票价格,Mind Medicine (MindMed) Inc.股票交易,Mind Medicine (MindMed) Inc.股票购买,Mind Medicine (MindMed) Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mind Medicine (MindMed) Inc.(MNMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}